Search: onr:"swepub:oai:lup.lub.lu.se:fe76189c-cdd8-4927-a624-a356c0d920a8" > Secondary Fracture ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 07114naa a2200817 4500 | |
001 | oai:lup.lub.lu.se:fe76189c-cdd8-4927-a624-a356c0d920a8 | |
003 | SwePub | |
008 | 200403s2020 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/fe76189c-cdd8-4927-a624-a356c0d920a82 URI |
024 | 7 | a https://doi.org/10.1097/BOT.00000000000017432 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Conley, Robert B.u Center for Medical Technology Policy4 aut |
245 | 1 0 | a Secondary Fracture Prevention : Consensus Clinical Recommendations from a Multistakeholder Coalition |
264 | 1 | c 2020 |
520 | a Osteoporosis-related fractures are undertreated, due in part to misinformation about recommended approaches to patient care and discrepancies among treatment guidelines. To help bridge this gap and improve patient outcomes, the American Society for Bone and Mineral Research assembled a multistakeholder coalition to develop clinical recommendations for the optimal prevention of secondary fractureamong people aged 65 years and older with a hip or vertebral fracture. The coalition developed 13 recommendations (7 primary and 6 secondary) strongly supported by the empirical literature. The coalition recommends increased communication with patients regarding fracture risk, mortality and morbidity outcomes, and fracture risk reduction. Risk assessment (including fall history) should occur at regular intervals with referral to physical and/or occupational therapy as appropriate. Oral, intravenous, andsubcutaneous pharmacotherapies are efficaciousandcanreduce risk of future fracture.Patientsneededucation,however, about thebenefitsandrisks of both treatment and not receiving treatment. Oral bisphosphonates alendronate and risedronate are first-line options and are generally well tolerated; otherwise, intravenous zoledronic acid and subcutaneous denosumab can be considered. Anabolic agents are expensive butmay be beneficial for selected patients at high risk.Optimal duration of pharmacotherapy is unknown but because the risk for second fractures is highest in the earlypost-fractureperiod,prompt treatment is recommended.Adequate dietary or supplemental vitaminDand calciumintake shouldbe assured. Individuals beingtreatedfor osteoporosis shouldbe reevaluated for fracture risk routinely, includingvia patienteducationabout osteoporosisandfracturesandmonitoringfor adverse treatment effects.Patients shouldbestronglyencouraged to avoid tobacco, consume alcohol inmoderation atmost, and engage in regular exercise and fall prevention strategies. Finally, referral to endocrinologists or other osteoporosis specialists may be warranted for individuals who experience repeated fracture or bone loss and those with complicating comorbidities (eg, hyperparathyroidism, chronic kidney disease). | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Ortopedi0 (SwePub)302112 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Orthopaedics0 (SwePub)302112 hsv//eng |
700 | 1 | a Adib, Gemmau Osteoporosis Centre, Damascus4 aut |
700 | 1 | a Adler, Robert A.u Hunter Holmes McGuire VA Medical Center4 aut |
700 | 1 | a Åkesson, Kristina E.u Lund University,Lunds universitet,Ortopedi - klinisk och molekylär osteoporosforskning,Forskargrupper vid Lunds universitet,Orthopedics - Clinical and Molecular Osteoporosis Research,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)orto-kak |
700 | 1 | a Alexander, Ivy M.u University of Connecticut4 aut |
700 | 1 | a Amenta, Kelly C.u Mercyhurst University4 aut |
700 | 1 | a Blank, Robert D.u Medical College of Wisconsin,Garvan Institute of Medical Research4 aut |
700 | 1 | a Brox, William Timothyu University of California, San Francisco4 aut |
700 | 1 | a Carmody, Emily E.u University of Rochester4 aut |
700 | 1 | a Chapman-Novakofski, Karenu University of Illinois at Urbana-Champaign4 aut |
700 | 1 | a Clarke, Bart L.u Mayo Clinic Minnesota4 aut |
700 | 1 | a Cody, Kathleen M.u American Bone Health4 aut |
700 | 1 | a Cooper, Cyrusu University of Southampton4 aut |
700 | 1 | a Crandall, Carolyn J.u University of California, Los Angeles4 aut |
700 | 1 | a Dirschl, Douglas R.u University of Chicago4 aut |
700 | 1 | a Eagen, Thomas J.u National Council on Aging4 aut |
700 | 1 | a Elderkin, Ann L.u American Society for Bone and Mineral Research4 aut |
700 | 1 | a Fujita, Masakiu International Osteoporosis Foundation, Switzerland4 aut |
700 | 1 | a Greenspan, Susan L.u University of Pittsburgh4 aut |
700 | 1 | a Halbout, Philippeu International Osteoporosis Foundation, Switzerland4 aut |
700 | 1 | a Hochberg, Marc C.u Baltimore Veterans Administration Medical Center,University of Maryland4 aut |
700 | 1 | a Javaid, Muhammadu University of Oxford4 aut |
700 | 1 | a Jeray, Kyle J.u Prisma Health4 aut |
700 | 1 | a Kearns, Ann E.u Mayo Clinic Minnesota4 aut |
700 | 1 | a King, Tobyu United States Bone and Joint Initiative (USBJI)4 aut |
700 | 1 | a Koinis, Thomas F.u Duke Primary Care Oxford4 aut |
700 | 1 | a Koontz, Jennifer Scottu University of Kansas,Newton Medical Center4 aut |
700 | 1 | a Kužma, Martinu University Hospital in Bratislava4 aut |
700 | 1 | a Lindsey, Carleenu Bristol Physical Therapy, LLC4 aut |
700 | 1 | a Lorentzon, Mattiasu University of Gothenburg,Sahlgrenska University Hospital,Australian Catholic University4 aut |
700 | 1 | a Lyritis, George P.u Hellenic Osteoporosis Foundation4 aut |
700 | 1 | a Michaud, Laura Boehnkeu University of Texas MD Anderson Cancer Center4 aut |
700 | 1 | a Miciano, Armandou Nevada Rehabilitation Institute4 aut |
700 | 1 | a Morin, Suzanne N.u McGill University4 aut |
700 | 1 | a Mujahid, Nadiau Brown University4 aut |
700 | 1 | a Napoli, Nicolau Sapienza University of Rome,Washington University in St. Louis4 aut |
700 | 1 | a Olenginski, Thomas P.u Geisinger Health System4 aut |
700 | 1 | a Puzas, J. Edwardu University of Rochester Medical Center4 aut |
700 | 1 | a Rizou, Stavroulau Hellenic Osteoporosis Foundation4 aut |
700 | 1 | a Rosen, Clifford J.u Maine Medical Center Research Institute,Tufts University4 aut |
700 | 1 | a Saag, Kennethu University of Alabama4 aut |
700 | 1 | a Thompson, Elizabethu National Osteoporosis Foundation4 aut |
700 | 1 | a Tosi, Laura L.u Children’s National Health System, Washington4 aut |
700 | 1 | a Tracer, Howardu Agency for Healthcare Research and Quality4 aut |
700 | 1 | a Khosla, Sundeepu Mayo Clinic Minnesota4 aut |
700 | 1 | a Kiel, Douglas P.u Harvard University4 aut |
710 | 2 | a Center for Medical Technology Policyb Osteoporosis Centre, Damascus4 org |
773 | 0 | t Journal of Orthopaedic Traumag 34:4, s. 125-141q 34:4<125-141x 0890-5339 |
856 | 4 | u http://dx.doi.org/10.1097/BOT.0000000000001743y FULLTEXT |
856 | 4 8 | u https://lup.lub.lu.se/record/fe76189c-cdd8-4927-a624-a356c0d920a8 |
856 | 4 8 | u https://doi.org/10.1097/BOT.0000000000001743 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.